
|Videos|February 13, 2013
Introduction: Advances and Issues in NSCLC
Advertisement
Episodes in this series

For High-Definition, Click
In the first installment of the series, the moderator, David R. Gandara, MD, provides an overview of the topics that will be discussed by the panel, which includes: Corey J. Langer, MD, Alan B. Sandler, MD, Mark A. Socinski, MD, and Anne S. Tsao, MD.
Gandara notes that this Peer Exchange discussion will focus on a range of issues and challanges facing physicians who treat patients with lung cancer. Specifically, the panel will examine new therapies and testing for molecular abnormalities and the integration of these test results into the treatment decision making process.
Advertisement
Related to this article

TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.

Yale experts address borderline resectability, perioperative chemoimmunotherapy, pCR-guided adjuvant therapy, and osimertinib in early-stage NSCLC.

Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.

Phase 3 SAFFRON data support EU and Japanese filings for savolitinib plus osimertinib in EGFR-mutated NSCLC with MET overexpression or amplification.

RELATIVITY-1093 is comparing nivolumab and relatlimab plus chemotherapy vs pembrolizumab plus chemotherapy in PD-L1–positive nonsquamous NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
4
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
5















